Jianbei Miao Miao (02161) plans to split Baoji Yuan and list independently on the main board of the Stock Exchange

Zhitong Finance App News, Jianbeimiao (02161) announced that the company proposed to split the Group's branded proprietary Chinese medicine products and traditional Chinese medicine clinic service business and list independently on the main board of the Stock Exchange by selling Baoji yuan and shares globally. The independent listing of Baoji Yuan and shares constitutes a matter of the Company's spin-off of Baoji Yuan and shares in accordance with Section 15 of the Application Guidelines.

As far as the proposed spin-off is concerned, the company has submitted an application to the Stock Exchange in accordance with Section 15 of the Application Guidelines. On June 26, 2026, the Listing Committee confirmed that the company could proceed with a proposed spin-off. On July 17, 2026, Pao Ji Yuan submitted a listing application form (Form A1) to the Stock Exchange to approve the listing and trading of Pao Ji Yuan and shares on the main board of the Stock Exchange.

As of the date of this announcement, Baoji Yuanhe is a wholly-owned subsidiary of the company. It is currently anticipated that after the proposed spin-off is completed, the company will hold no less than 50% of the total issued share capital, while Baoji Yuanhe will continue to be a subsidiary of the company.

According to reports, the spin-off group is a proprietary Chinese medicine group in Hong Kong. Relying on a vertically integrated traditional Chinese medicine business model, it has a series of highly trusted traditional Chinese medicine brands as the core, has multiple refined formulations, has accurate curative effects on indications, and is mainly engaged in manufacturing, marketing and distributing branded proprietary Chinese medicine products and providing traditional Chinese medicine clinic services.